Involvement of MIR-126 and MMP9 in the Pathogenesis of Intra-Abdominal Fistulizing Crohn's Disease: A Brief Research Report.
Crohn’s disease
MMP9
intra-abdominal fistulas
miRNA
surgery
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
11
2021
accepted:
22
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Intra-abdominal fistulas are complications that affect a significant proportion of Crohn's disease patients, often requiring surgery. The aim of the present work was to correlate the occurrence of intestinal fistulization to the clinico-pathological features of these patients and to the plasma levels of MMP9, a gelatinase involved in the pathophysiology of fistula formation, and of miR-126, appearing to modulate MMP9 expression. In a series of 31 consecutive Crohn's patients admitted to surgery due to therapeutic failure and/or complicated disease, we identified nine cases of abdominal fistulas, mainly entero-enteric fistulas. MMP9 protein was determined in plasma and at the intestinal level using immunometric assays. Circulating miR-126 was also measured in all plasma samples by real-time PCR. Comparing patients with and without intra-abdominal fistulas, we did not observe differences in terms of age, gender, disease location and duration, number of previous surgeries and pre-biologic medications. However, cases with intra-abdominal fistulas had a significantly higher CDAI ( These data confirm that circulating MMP9 can be used for the identification of cases with intra-abdominal fistulas and suggest that miR-126 may be also involved in the pathogenesis of this complication and that it may be further investigated as a new therapeutic strategy or for monitoring therapeutic response in these patients.
Sections du résumé
Background
UNASSIGNED
Intra-abdominal fistulas are complications that affect a significant proportion of Crohn's disease patients, often requiring surgery. The aim of the present work was to correlate the occurrence of intestinal fistulization to the clinico-pathological features of these patients and to the plasma levels of MMP9, a gelatinase involved in the pathophysiology of fistula formation, and of miR-126, appearing to modulate MMP9 expression.
Methods
UNASSIGNED
In a series of 31 consecutive Crohn's patients admitted to surgery due to therapeutic failure and/or complicated disease, we identified nine cases of abdominal fistulas, mainly entero-enteric fistulas. MMP9 protein was determined in plasma and at the intestinal level using immunometric assays. Circulating miR-126 was also measured in all plasma samples by real-time PCR.
Results
UNASSIGNED
Comparing patients with and without intra-abdominal fistulas, we did not observe differences in terms of age, gender, disease location and duration, number of previous surgeries and pre-biologic medications. However, cases with intra-abdominal fistulas had a significantly higher CDAI (
Conclusions
UNASSIGNED
These data confirm that circulating MMP9 can be used for the identification of cases with intra-abdominal fistulas and suggest that miR-126 may be also involved in the pathogenesis of this complication and that it may be further investigated as a new therapeutic strategy or for monitoring therapeutic response in these patients.
Identifiants
pubmed: 35620197
doi: 10.3389/fsurg.2022.822407
pmc: PMC9127299
doi:
Types de publication
Journal Article
Langues
eng
Pagination
822407Informations de copyright
Copyright © 2022 Luceri, D'Ambrosio, Bigagli, Cinci, Russo, Staderini, Cricchio, Giudici and Scaringi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Inflamm Bowel Dis. 2008 Aug;14(8):1091-6
pubmed: 18338781
Lab Invest. 2020 Dec;100(12):1564-1574
pubmed: 32612287
PLoS One. 2012;7(12):e52782
pubmed: 23285182
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e803-e809
pubmed: 34678857
Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):92-106
pubmed: 19153563
Reprod Sci. 2022 Jun;29(6):1667-1673
pubmed: 34159571
Inflamm Bowel Dis. 2020 Sep 18;26(10):1597-1606
pubmed: 32793975
Int J Med Sci. 2013 Dec 10;11(1):17-23
pubmed: 24396282
Reprod Sci. 2018 Jul;25(7):978-979
pubmed: 28100109
Inflamm Bowel Dis. 2016 Sep;22(9):2041-57
pubmed: 27542125
Int J Colorectal Dis. 2004 Sep;19(5):481-5; discussion 486
pubmed: 15168043
Inflamm Bowel Dis. 2017 May;23(5):739-752
pubmed: 28426456
Am J Physiol Gastrointest Liver Physiol. 2013 May 1;304(9):G793-803
pubmed: 23471340
Gut. 2004 May;53(5):701-9
pubmed: 15082589
Diagnostics (Basel). 2020 Jun 02;10(6):
pubmed: 32498419
Hereditas. 2019 Apr 09;156:11
pubmed: 31007650
Therap Adv Gastroenterol. 2019 Oct 09;12:1756284819881590
pubmed: 31636712
Dig Surg. 2002;19(1):36-9
pubmed: 11961353
World J Surg. 2010 Aug;34(8):1924-9
pubmed: 20372893